Floatz logo

Romidepsin

Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor

City of Hope Medical CenterSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor cohort.

Asset / SponsorPhaseRating
Cediranib
National Cancer Institute (NCI)
Phase 2BBB
Cixutumumab
National Cancer Institute (NCI)
Phase 2BB
Irinotecan
Gradalis, Inc.
Phase 3BB
Eloxatin
National Cancer Institute (NCI)
Phase 2BB
Evomela
M.D. Anderson Cancer Center
Phase 2B

View all 31 →

Same molecule, other indications

Romidepsin is also rated in:

Myelodysplastic/Myeloproliferative DiseasesDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent Mycosis Fungoides/Sezary SyndromeDormant
BBB
Indicative ·
75 / 100
View asset →
Multiple Myeloma and Plasma Cell NeoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →